Information Provided By:
Fly News Breaks for January 31, 2020
Jan 31, 2020 | 05:25 EDT
JPMorgan analyst Jessica Fye upgraded Arena Pharmaceuticals to Overweight from Neutral with a $58 price target.
News For ARNA From the Last 2 Days
Aug 5, 2021 | 07:47 EDT
Second Genome announced they are entering a strategic collaboration with Arena Pharmaceuticals to identify microbiome biomarkers associated with clinical response for their lead program in gastroenterology, etrasimod. Under the terms of the agreement, Second Genome will utilize its proprietary sg-4-sight discovery engine to identify microbiome biomarkers associated with clinical benefit or adverse effects observed within data from the CULTIVATE clinical trial. Arena's CULTIVATE trial is a Phase 2/3 clinical trial evaluating the efficacy and safety of etrasimod, a next-generation, once-daily, oral, highly selective sphingosine 1-phosphate receptor modulator, in patients with moderately-to-severely active Crohn's disease. This work will help inform patient stratification and optimize potential treatments for patients in the future.